Matricelf has reached a major milestone

News provided by

May 02, 2022, 09:00 ET

Succeeding for the first time to produce in-house induced pluripotent stem cells from human peripheral blood cells

TEL AVIV, Israel, May 2, 2022 /PRNewswire/ -- Matricelf (TASE: MTLF) reported yesterday (May 1st, 2022) that it succeeded to produce in-house induced pluripotent stem cells (iPSC's) from human peripheral blood cells.

The company reprogramed the cells to iPSC's which presented specific characteristics of differentiation as pluripotent stem cells as expected to present.

Induced Pluripotent stem cells have the ability to differentiate into different cell types, including neural cells, and by combining the cells with the unique hydrogel, developed by the company, will compose the autologous 3D neural implant for paralyzed patients following Spinal Cord Injury.

Matricelf is developing 3D autologous implants for the regeneration of damaged tissues using a cellular and extra cellular component that are both originated from the patients themselves.

The implant manufacturing process combines a proprietary technology to produce a thermo-responsive hydrogel using the patient's omentum (intra-abdominal fat tissue) and iPSC's generated by reprograming mature cells from the patient's peripheral blood.

The company believes that self-manufacturing of iPSC's is an important milestone accomplished by the R&D team as part of the pre-clinical company's R&D program. The ability to independently produce iPSC's, in parallel to the completion of the hydrogel development, is a crucial step towards end-to-end independent manufacturing capacity of neural tissue implants.

Matricelf CEO, Asaf Toker MD, said, "Our ability to independently produce human iPSC's is a huge achievement of the R&D team both in the scientific and business aspects. The ability to produce iPSC's without the need to rely on external sub contractures positions the company as a central player in cellular therapy and regenerative medicine industry and will reduce future manufacturing costs. We believe that independent manufacturing capacity of iPSCs is a remarkable economic opportunity in billions of USD market per year dealing with spinal cord injury, and in the future for a variety of other medical conditions."

Matricelf VP R&D, Tamar Harel Adar PhD, said, "The process of reprograming mature cells into iPSC, that present the potential to differentiate to any cell type is a revolutionary and promising technology in the world of cellular therapy and regenerative medicine. Independent manufacturing capabilities of iPSC's is a result of intensive work by the R&D team that is based on acquiring and developing applicable know-how and scientific tools. The ability to manufacture iPSC's from the patients own mature cells is significant since it enables the company to produce new tissues to replace various human damaged tissues in a variety of medical conditions."

About Matricelf:

Matricelf (TASE:MTLF) is an Israeli biotechnology company in the field of regenerative medicine and tissue engineering.

The company develops a platform for autologous (personal) 3D printing of tissues and organs that significantly reduce the risk of implant rejection.

The company, founded in 2019, by Alon Sinai and Prof Tal Dvir who serves as the company chief scientist.

The company is based in Ness Ziona, Israel and has 11 employees.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates", "destroys" and similar expressions or variations of such words are intended to identify forward-looking statements.

Because such statements deal with future events and are based on Matricelf's current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of Matricelf could differ materially from those described in or implied by the statements in this press release.

For additional information:

www.matricelf.com

[email protected]

SOURCE Matricelf